We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ZIM:NYSEZIM Integrated Shipping Services Ltd. Analysis

Data as of 2026-07-18 - not real-time

$24.30

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The stock is trading just above a key support level, with the 20‑day moving average sitting slightly below the 50‑day average, while the 200‑day average remains comfortably lower, suggesting a neutral short‑term bias but an underlying longer‑term uptrend. RSI hovers in the mid‑range and the MACD has turned bearish, reinforced by a modestly negative histogram, indicating limited upside momentum. Volume has been picking up, yet the 30‑day volatility is high and the beta is near market, meaning price swings can be pronounced. The market sentiment index reads “Extreme Greed,” but the DCF model only signals a marginal upside, and the dividend yield, while attractive, is backed by a payout ratio well above sustainable levels.
Fundamentally, revenue has contracted sharply and operating margins are thin, while the balance sheet shows a debt load that dwarfs equity, creating leverage concerns. Forward earnings are projected negative, and the ongoing merger with Hapag‑Lloyd faces regulatory scrutiny and political resistance, adding a layer of regulatory and geographic risk. These dynamics, combined with the modest valuation gap and high dividend payout, suggest caution despite the short‑term price resilience.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • bearish MACD and price near support
  • regulatory and political opposition to merger
  • unsustainable dividend payout

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • potential merger synergies if approved
  • valuation close to fair value
  • high volatility and leverage

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • integration prospects post‑merger
  • industry cyclicality and demand recovery
  • need to deleverage balance sheet

Key Metrics & Analysis

Financial Health

Revenue Growth-30.40%
Profit Margin1.55%
P/E Ratio29.6
ROE2.54%
ROA2.10%
Debt/Equity143.11
P/B Ratio0.8
Op. Cash Flow$1.7B
Free Cash Flow$637.7M
Industry P/E30.8

Technical Analysis

TrendNeutral
RSI45.5
Support$23.28
Resistance$26.07
MA 20$24.84
MA 50$25.17
MA 200$22.50
MACDBearish
VolumeIncreasing
Fear & Greed Index87.91

Valuation

Fair Value$36.90
Target Price$24.95
Upside/Downside2.67%
GradeFair
TypeBlend
Dividend Yield7.88%

Risk Assessment

Beta0.99
Volatility38.41%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.